A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors

Clinical Trial Details

This clinical trial is for men and women with advanced cancer or cancer that has spread to other parts of the body, and have either not tolerated the standard therapy, or there is no standard therapy available.

The purpose of this study is to test the safety of an investigational (experimental) drug, TAC-001, to see what effects it has on the cancer. Investigational means that it is not yet approved by the U.S. Food and Drug Administration (FDA).

TAC-001 will be administered intravenously with adjustment for each participant's body size at every cycle. The study team will discuss dosing with everyone individually.

Participation is expected to last up to 2 years.

Key Eligibility:

Participants must be 18 years of age or older.
Participants must have solid tumors who have progressed on or are intolerant to standard therapy, for which no standard therapy is available.

Detailed eligibility will be reviewed when you contact the study team.

Return to List